Shares of 10x Genomics, Inc. (TXG) are soaring 13.88% in Friday's trading session, following the company's impressive third-quarter 2025 financial results and a wave of positive analyst reactions. The biotech firm, known for its innovative genomics and single-cell analysis technologies, reported better-than-anticipated earnings and revenue figures, sparking investor enthusiasm.
For the third quarter, 10x Genomics posted earnings per share (EPS) of $(0.22), beating the estimated $(0.29). Revenue came in at $149.002 million, surpassing the forecast of $142.490 million. The company's gross margin stood at a healthy 67%, indicating strong profitability in its core operations. Despite reporting a net loss of $27.5 million for the quarter, the narrower-than-expected loss bolstered investor confidence.
Adding to the positive sentiment, 10x Genomics provided an optimistic outlook for the fourth quarter, projecting revenue between $154 million and $158 million, which exceeded analysts' expectations of $154.1 million. This forward-looking guidance suggests continued growth and appears to have contributed significantly to the stock's rally. In response to the strong results and outlook, several analysts have raised their price targets for 10x Genomics. JP Morgan increased its target price to $15 from $13, while Barclays raised its target to $17 from $15, further fueling investor optimism. The combination of better-than-expected financial performance, upbeat guidance, and positive analyst revisions has created a perfect storm for 10x Genomics' stock, driving the substantial gain in today's trading session.
Comments